| Sumario: | The article looks at Dr. Brian Druker, focusing on his efforts to develop medication for cancer patients. The author comments on Druker's background at the Dana-Farber Cancer Institute and also mentions how his devotion to cancer treatment research led to his divorce. The effects of chemotherapy on white blood cells is discussed, noting how the drug STI571 does not damage healthy cells. The author comments on how Druker directly sought the approval of the U.S. Food and Drug Administration to begin human trials for the drug. LaDonna Lopossa, a cancer patient who benefited from trials of STI571, is also mentioned.
|
|---|